A new concept for the treatment of cancer
Crystal structure of human MTH1 in complex with a key inhibitor.
Source: Stockholm University, Prof. Pal Stenmark.
A team of researchers from five Swedish universities has identified a new way to treat cancer. They present their concept in the journal „Nature“. It is based on inhibiting a specific enzyme called MTH1. Cancer cells, unlike normal cells, need MTH1 to survive. Without this enzyme, oxidized nucleotides are incorporated into DNA, resulting in lethal DNA double-strand breaks in the cancer cells. The research group at Stockholm University has determined the structure of MTH1 based on diffraction measurements at HZB´s MX-beamline at BESSY II. These detailed structural studies are important for the development of efficient inhibitors targeting MTH1.
In recent decades, the development of new anticancer agents focused on targeting specific genetic defects in cancer cells. These often are effective initially, but later cause trouble due to emerging rapid resistance. In the current study, the researchers present a general enzymatic activity that all cancers tested rely on and that seems to be independent of the genetic changes found in specific cancers. The research team shows that all the investigated cancer tumours need the MTH1 enzyme to survive. In this respect, cancer cells differ from normal cells, which do not need this enzyme.
“The concept is built on the fact that cancer cells have an altered metabolism, resulting in oxidation of nucleotide building blocks,” says Thomas Helleday, professor at Karolinska Institutet, who leads the study: "MTH1 repairs the oxidized building blocks, preventing the oxidative stress from being incorporated into DNA and becoming DNA damage. This allows replication in cancer cells so they can divide and multiply. With an MTH1 inhibitor, the enzyme is blocked and damaged nucleotides enter DNA, causing damage and killing cancer cells."
Normal cells do not need MTH1 as they have regulated metabolism preventing damage of nucleotide building blocks. Finding a general enzymatic activity required only for cancer cells to survive opens up a whole new way of treating cancer.
Original publication:
“MTH1 inhibition kills cancer by preventing sanitation of the dNTP pool”, Helge Gad, Tobias Koolmeister, Ann-Sofie Jemth et al., Nature, online 2 April 2014, doi: 10.1038/nature13181. http://dx.doi.org/10.1038/nature13181.
“Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy”, Kilian V. M. Huber, Eidarus Salah, Branka Radic et al., Nature, online 2 April 2014, doi: 10.1038/nature13194. http://dx.doi.org/10.1038/nature13194
- 5000th protein structure at BESSY II: Starting point for a COVID drugMany proteins have a complex architecture that enables biological functions. Molecules can bind to specific sites on a protein and alter its function. A team at HZB has now investigated the Nsp1 protein, which plays a role in infection with the SARS-CoV-2 virus. They analysed protein crystals, previously mixed with molecules from a fragment library, and discovered a total of 21 candidates as starting points for drug development. At the same time, they also decoded the 5000th structure at BESSY II.
- What Zinc concentration in teeth revealsTeeth are composites of mineral and protein, with a bulk of bony dentin that is highly porous. This structure is allows teeth to be both strong and sensitive. Besides calcium and phosphate, teeth contain trace elements such as zinc. Using complementary microscopy imaging techniques, a team from Charité Berlin, TU Berlin and HZB has quantified the distribution of natural zinc along and across teeth in 3 dimensions. The team found that, as porosity in dentine increases towards the pulp, zinc concentration increases 5~10 fold. These results help to understand the influence of widely-used zinc-containing biomaterials (e.g. filling) and could inspire improvements in dental medicine.
- Fascinating archaeological find becomes a source of knowledgeThe Bavarian State Office for the Preservation of Historical Monuments (BLfD) has sent a rare artefact from the Middle Bronze Age to Berlin for examination using cutting-edge, non-destructive methods. It is a 3,400-year-old bronze sword, unearthed during archaeological excavations in Nördlingen, Swabia, in 2023. Experts have been able to determine how the hilt and blade are connected, as well as how the rare and well-preserved decorations on the pommel were made. This has provided valuable insight into the craft techniques employed in southern Germany during the Bronze Age. The BLfD used 3D computed tomography and X-ray diffraction to analyse internal stresses at the Helmholtz-Zentrum Berlin (HZB), as well as X-ray fluorescence spectroscopy at a BESSY II beamline supervised by the Bundesanstalt für Materialforschung und -prüfung (BAM).